What's new? Log in Free sign up

Morphosys (MOR) News and press releases

Company Profile

News

From Benzinga Pro

National Instruments, Virgin Galactic And Other Big Stocks Moving Higher On Friday

News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas

U.S. stocks traded slightly higher, with the Dow Jones gaining around 25 points on Friday. Here are some big stocks recording gains in today’s session.

JP Morgan Downgrades MorphoSys to Underweight

News, Downgrades, Analyst Ratings

JP Morgan analyst Richard Vosser downgrades MorphoSys (NASDAQ:MOR) from Neutral to Underweight.

Stocks That Hit 52-Week Lows On Friday

OnFriday, 143 stocks hit new 52-week lows.

Stocks That Hit 52-Week Lows On Tuesday

On Tuesday, 298 companies achieved new lows for the year.

Why Avaya Holdings Shares Are Trading Lower By 62%? Here Are 62 Stocks Moving In Friday's Mid-Day Session

News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas

Gainers Allarity Therapeutics, Inc. (NASDAQ: ALLR) gained 240% to $0.90. Allarity Therapeutics, last month, posted a Q3 loss of $0.68 per share.

Stocks That Hit 52-Week Lows On Friday

During Friday's trading, 293 companies set new 52-week lows.

12 Health Care Stocks Moving In Friday's Pre-Market Session

Why Adobe Shares Are Trading Higher; Here Are 31 Stocks Moving Premarket

News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Trading Ideas

Gainers Minim, Inc. (NASDAQ: MINM) shares rose 66.5% to $0.2903 in pre-market trading after gaining over 10% on Thursday. Minim, last month, reported worse-than-expected results.

Guardant Health, Novavax And Some Other Big Stocks Moving Lower In Today's Pre-Market Session

News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas

U.S. stock futures traded lower this morning. Here are some big stocks recording losses in today’s pre-market trading session.

MorphoSys Presented New Longer-term Phase 2 Results on Pelabresib in Myelofibrosis, Including Potential Disease-Modifying Activity, at ASH 2022

MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced results from analyses of the ongoing MANIFEST study, an open-label Phase 2 clinical trial of pelabresib, an investigational BET inhibitor, in patients with myelofibrosis, a type of bone marrow cancer with limited treatment options.

MorphoSys Inks Licensing Agreement With Novartis For Preclinical Cancer Programs

Biotech, Large Cap, News, Penny Stocks, Health Care, Contracts, Small Cap, General

MorphoSys Shares Higher Premarket After Co Announced on Tuesday an Upfront Payment of $23M from Novartis for Exclusive Worldwide Rights for Pre-clinical Inhibitors of a Novel Cancer Target

MorphoSys announced on Tuesday, that its fully owned subsidiary Constellation Pharmaceuticals, Inc. has entered into a global licensing agreement with Novartis to research, develop and commercialize its pre-clinical inhibitors of a novel cancer target. This program was added to MorphoSys' research portfolio following its acquisition of Constellation Pharmaceuticals, Inc.

Is The Oil And Gas Bull Market Over? This 2X Leveraged ETF Inversely Tracks Exxon, Occidental And More

Long Ideas, Sector ETFs, Short Ideas, Technicals, Commodities, Top Stories, Markets, Movers, Trading Ideas, ETFs

The Direxion Daily S&P Oil & Gas Exp & Prod Bear 2X Shares (NYSE: DRIP) was surging Monday after the Group of Seven (G7) nations and the European Union agreed to put a price cap of

JMP Securities Maintains Market Outperform on MorphoSys, Lowers Price Target to $15

News, Price Target, Analyst Ratings

JMP Securities analyst Jason Butler maintains MorphoSys (NASDAQ:MOR) with a Market Outperform and lowers the price target from $32 to $15.

Stocks That Hit 52-Week Lows On Wednesday

On Wednesday, 70 companies set new 52-week lows.

Earnings Scheduled For November 16, 2022

Companies Reporting Before The Bell • Golden Ocean Group (NASDAQ:GOGL) is estimated to report earnings for its third quarter.

MorphoSys Earnings Preview

Why Infinity Pharmaceuticals Shares Tumbled Around 38%; Here Are 79 Biggest Movers From Yesterday

News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas

Gainers Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT) shares surged 113.8% to settle at $20.10 on Monday. Indivior PLC agreed to acquire Opiant Pharmaceuticals for $20.00 per share in cash, plus contingent value rights (CVRs) of up to $8.00 per share.

Roche's Alzheimer's Flop Trial Removes One Competitor, But Reimbursement Debate Lingers

Analyst Color, Biotech, Large Cap, News, Penny Stocks, Health Care, Small Cap, Analyst Ratings, Movers, Trading Ideas, General

Why Opiant Pharmaceuticals Shares Are Trading Higher By 115%? Here Are 53 Stocks Moving In Monday's Mid-Day Session

News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas

Gainers Freight Technologies, Inc. (NASDAQ: FRGT) shares surged 137% to $0.4901 after analysts at Chardan Capital initiated coverage of the stock with a $2.25 price target.

Press releases

From Benzinga Pro

MorphoSys AG: MorphoSys Expects Topline Data from Phase 3 Study of Pelabresib in Myelofibrosis in Early 2024

News, Events, Press Releases

MUNICH, GERMANY / ACCESSWIRE / January 9, 2023 / MorphoSys AG ((FSE: MOR, NASDAQ:MOR) announced today that topline data from the ongoing Phase 3 MANIFEST-2 study - a global, randomized, double-blind clinical trial

MorphoSys Reports Preliminary 2022 Monjuvi U.S. Net Product Sales, Provides 2023 Financial Guidance and Reduces Financial Liability

Legal, Press Releases

Preliminary 2022 Monjuvi U.S. net product sales of US$ 89.4 million ( € 84.9 million)Anticipated 2023 Monjuvi U.S. net product sales in the range of US$ 80 to 95 millionPreliminary unaudited financial

MorphoSys AG: Financial Calendar 2023

PLANEGG / MUNICH, GERMANY / ACCESSWIRE / November 28, 2022 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) publishes its financial calendar dates for the year 2023:Publication of Interim Statement / ReportConference CallYear-End

MorphoSys AG Reports First Nine Months and Third Quarter 2022 Financial Results

– Monjuvi® U.S. net product sales of US$ 22.2 million (€ 21.9 million) for the third quarter of 2022 – Presentation of preliminary results from phase 1/2 study of tulmimetostat (CPI-0209) supporting its potential

MorphoSys' Licensing Partner Roche Provides Update on Phase 3 GRADUATE Program for Gantenerumab in Early Alzheimer's Disease

News, Press Releases

GRADUATE studies did not meet primary endpointPLANEGG / MUNICH, GERMANY / ACCESSWIRE / November 14, 2022 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) announced today that its licensing partner Roche ((SIX: RO, ROG, OTCQX:RHHBY)

Invitation to MorphoSys' Third Quarter and First Nine Months 2022 Results Conference Call on November 17, 2022

Earnings, Press Releases

Conference Call AlertPLANEGG/MUNICH, GERMANY / ACCESSWIRE / November 10, 2022 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) will publish its results for the third quarter and first nine months 2022 results on November 16, 2022 at